ABSTRACT
Targeted radionuclide therapy (i.e. the systemic administration of radionuclides or radiolabeled drugs directed against tumor-associated targets) is a nuclear medicine technique gaining increasing space in different clinical settings. Peptide receptor radionuclide therapy (PRRT), based on somatostatin receptor (SSTR) overexpression in neuroendocrine tumors (NETs), is one of the most known nuclear medicine therapeutic approaches in clinical practice. The improvement of diagnostic imaging accuracy in NETs, along with the therapeutic efficacy and the good tolerability of PRRT, has had a great impact on patient management. Moreover, the possibility to evaluate receptor expression in other malignancies is widening the possible indications for PRRT. Hereafter we explain the main radiopharmaceutical, clinical, and dosimetric aspects of PRRT and its possible future fields of application.
